Drugs / TOVETUMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01102400 | Mar 2010 → Nov 2012 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00816400 | Mar 2009 → Jan 2012 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT01268059 | Dec 2010 → Sep 2013 | non-small cell lung carcinoma | MedImmune LLC | Terminated | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01268566 | Jan 2011 → Nov 2012 | glioblastoma | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOVETUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2364651 ↗ |
| Known as | MEDI-575 | “MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease...” NCT01268059 ↗ |
| Modality | Monoclonal antibody | “a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα)” NCT00816400 ↗ |
| Route | Intravenous | “MEDI-575 as an IV infusion” NCT00816400 ↗ |
| Target | PDGFRA | “Platelet-derived Growth Factor Receptor Alpha (PDGFRα)” NCT00816400 ↗ |